Status:
UNKNOWN
Calcitriol Supplementation in COVID-19 Patients
Lead Sponsor:
RenJi Hospital
Conditions:
COVID-19
Vitamin D Deficiency
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This is a randomized, open label study to evaluate the efficacy and safety of calcitriol supplementation in COVID-19 patients with vitamin D deficiency.
Detailed Description
This is a randomized, open label study to evaluate the efficacy （clinical and laboratory change）and safety （serum calcium） of calcitriol supplementation in COVID-19 patients with vitamin D deficiency.
Eligibility Criteria
Inclusion
- Hospitalized symptomatic COVID-19 patients;
- COVID-19 nucleic acid Ct value \< 28 (both orf1ab gene Ct value and N gene Ct value \< 28);
- Vitamin D deficiency: 25OHD ≤ 20ng/ml;
- Age: 18-70 years old;
Exclusion
- Asymptomatic COVID-19 patients ；
- Hypercalcemia;
- History of primary hyperparathyroidism;
- History of triple hyperparathyroidism;
- Patients who are allergic to calcitriol;
- Pregnant or lactating women;
- Patients with severe heart or lung diseases or tumor history;
- Patients already taking vitamin D or its similar preparations;
- Participants in other interventional clinical studies (including taking paxlovid);
- Patients with renal insufficiency (eGFR\<60ml/min/1.73m2);
- Patients considered unsuitable for this study by the investigator；
Key Trial Info
Start Date :
June 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 19 2022
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT05415254
Start Date
June 12 2022
End Date
September 19 2022
Last Update
June 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital
Shanghai, Shanghai Municipality, China, 200127